Weill Cornell Lymphoma Program

Weill Cornell Lymphoma Program Enabling patients with lymphoma to have the best possible clinical outcomes.

The Lymphoma Program at Weill Cornell Medical College/NewYork-Presbyterian Hospital, located on the Upper East Side of New York City, is internationally recognized for our efforts to enable patients with non-Hodgkin’s lymphoma, Hodgkin’s disease and related disorders to have the best possible clinical outcome, including cure when possible. The goal of our page and blog is to provide you with up-to-date information about the latest developments in lymphoma treatment and research.

In another VJHemOnc video, Dr. Elisa ten Hacken discussed the genetic and metabolic drivers of Richter's transformation:...
01/22/2026

In another VJHemOnc video, Dr. Elisa ten Hacken discussed the genetic and metabolic drivers of Richter's transformation:

Elisa Ten Hacken, PhD, Weill Cornell Medicine, New York, NY, briefly discusses the genetic and metabolic drivers of Richter’s transformation,...

Dr. Erin Mulvey joined a roundtable discussion featuring   experts from across the US to discuss the use of BTK inhibito...
01/20/2026

Dr. Erin Mulvey joined a roundtable discussion featuring experts from across the US to discuss the use of BTK inhibitors for chronic lymphocytic ( ):

Experts debate covalent vs noncovalent BTK inhibitors in CLL, unpacking new ASH-era data, safety signals, and sequencing gaps.

WATCH: Dr. Elisa ten Hacken spoke with VJHemOnc about the progression from chronic lymphocytic leukemia ( ) to Richter’s...
01/17/2026

WATCH: Dr. Elisa ten Hacken spoke with VJHemOnc about the progression from chronic lymphocytic leukemia ( ) to Richter’s transformation:

Elisa Ten Hacken, PhD, Weill Cornell Medicine, New York, NY, discusses preclinical research using CRISPR-Cas9 engineered immunocompetent mouse models to...

Dr. Erin Mulvey joined a panel of   experts to discuss BTK inhibitors for the treatment of chronic lymphocytic leukemia ...
12/22/2025

Dr. Erin Mulvey joined a panel of experts to discuss BTK inhibitors for the treatment of chronic lymphocytic leukemia (CLL):

Experts debate covalent vs noncovalent BTK inhibitors in CLL, unpacking new ASH-era data, safety signals, and sequencing gaps.

12/19/2025

Dr. Sarah Rutherford presented at on improving outcomes in diffuse large B-cell (DLBCL). Learn more: https://bit.ly/4ajfGtc

Listen to Dr. Sarah Rutherford on the OncLive On Air   where she discusses the use of circulating tumor DNA (ctDNA) to h...
12/16/2025

Listen to Dr. Sarah Rutherford on the OncLive On Air where she discusses the use of circulating tumor DNA (ctDNA) to help shape treatment strategies:

Dr Rutherford discusses the use of ctDNA testing for guiding lymphoma management and trials that seek to determine the best use of this type of assay.

  expert Dr. Richard Furman and Dr. Gail Roboz of the Weill Cornell Leukemia Program  joined the Weill Cornell Medicine ...
12/11/2025

expert Dr. Richard Furman and Dr. Gail Roboz of the Weill Cornell Leukemia Program joined the Weill Cornell Medicine podcast to talk about the they were most excited about. Listen here:

Podcast Episode · CancerCast · 12/03/2025 · 1 sec

11/25/2025

At , Dr. John Allan highlighted progress in for frontline chronic lymphocytic leukemia (CLL) doublet and triplet treatment regimens: https://bit.ly/4o3C3pt

Watch Dr. Jia Ruan talk about emerging targeted therapies for peripheral T-cell   in this Oncology Learning Network vide...
11/21/2025

Watch Dr. Jia Ruan talk about emerging targeted therapies for peripheral T-cell in this Oncology Learning Network video from :

Jia Ruan, MD, shares insights into novel targeted therapies for patients with peripheral T-cell lymphoma at the 2025 Lymphoma, Leukemia, & Myeloma Congress.

Dr. Sarah Rutherford’s talk at   on a combination therapy for   was mentioned as one of the most notable conference pres...
11/07/2025

Dr. Sarah Rutherford’s talk at on a combination therapy for was mentioned as one of the most notable conference presentations in this Healio video:

In this video, Leo I. Gordon, MD, FACP, discusses notable presentations from Lymphoma, Leukemia & Myeloma Congress.

10/31/2025

Dr. Sarah Rutherford outlined strategies for treating elderly patients with including how she approaches treatment and the use of combination and regimens: https://bit.ly/47sAife

Watch Dr. Erin Mulvey explain emerging treatments for relapsed/refractory Follicular   at  : https://bit.ly/4nkXMZH (cc:...
10/29/2025

Watch Dr. Erin Mulvey explain emerging treatments for relapsed/refractory Follicular at : https://bit.ly/4nkXMZH (cc: Oncology Learning Network)

Erin Mulvey, MD, discusses novel treatment options for patients with relapsed/refractory follicular lymphoma at the 2025 Lymphoma, Leukemia & Myeloma Congress.

Address

520 East 70th Street, Starr Pavilion, 3rd Floor
New York, NY
10065

Alerts

Be the first to know and let us send you an email when Weill Cornell Lymphoma Program posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category

Our Story

The Lymphoma Program at Weill Cornell Medicine and NewYork-Presbyterian Hospital is one of the leading clinical and scientific research centers in the world. The renowned experts that comprise our team are committed to delivering compassionate, cutting-edge care to improve the lives of people with lymphoma before, during and for years after treatment.

We are not content to care only for current lymphoma patients; we also actively pursue medical advances that will alleviate the suffering of those affected by the disease in the future. Whether acting as your primary oncologist, working in tandem with your oncologist or primary physician, overseeing your participation in a clinical trial or providing a second opinion, we are pleased to help all patients achieve the best possible results.